A major challenge in continuous fetal monitoring is that both the fetus and the umbilical cord are constantly moving. To address this, the researchers developed autonomous tracking algorithms that ...

On the earnings call in August, new CEO Katie Szyman, who joined Masimo in February from BD, sought to reassure investors that the company’s decades-long relationship with Philips remained strong.

However, A1C isn’t your only option for tracking your blood sugar levels: Continuous glucose monitors (CGMs) have moved beyond type 1 diabetes care to being an important tool for type 2 management as ...

is a senior reporter and author of the Optimizer newsletter. She has more than 13 years of experience reporting on wearables, health tech, and more. Before coming to The Verge, she worked for Gizmodo ...

Continuous glucose monitoring (CGM) is no longer limited to type 1 diabetes (T1D) and may play a significant role in shaping the care of type 2 diabetes (T2D). Emerging evidence indicates that broader ...

Bridger Management sold 47,841 shares of Masimo in the fourth quarter. The move resulted in the quarter-end position value decreasing by $7.06 million. The position was previously 3.8% of fund AUM as ...

Irvine-based health technology and consumer electronics firm Masimo Corp. announced it entered into a definitive agreement to be acquired by healthcare company Danaher Corporation (Danaher). Under the ...

Forbes contributors publish independent expert analyses and insights. I’m a founder, writer and lecturer focusing on VC funds. This voice experience is generated by AI. Learn more. This voice ...

Global life sciences giant Danaher coughed up a pretty penny to buy Masimo this week, spending roughly $10 billion to beef up its diagnostics portfolio. The deal values medical device developer Masimo ...

A deal with Danaher Corp. follows a tumultuous few years for Masimo, marked by a proxy fight that led to the resignation of its founder and CEO and a cyberattack that slowed production at its ...

Danaher will acquire pulse oximeter maker Masimo in a $9.9 billion deal, as the life science firm looks to bulk up its diagnostics portfolio. The companies said on Tuesday that Danaher will pay $180 ...

Feb 17 (Reuters) - Danaher (DHR.N), opens new tab, a $150 billion U.S. company that makes tools used in developing and testing medicines, on Tuesday agreed to buy Masimo (MASI.O), opens new tab for $9 ...